# US 11,406,681 B2 · Compound for treating oxidative stress in mammals > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,406,681 B2 - Document ID: US11406681B2 - Status: Granted - Kind: B2 - Application number: 17/501,309 - Filed: 2021-10-14 - Published: 2022-02-03 - Granted: 2022-08-09 - Earliest claimed: 2019-12-23 - Assignees: Hemopet - Applicants: Hemopet - Inventors: Winifred Jean Dodds - Web page: https://patentgrep.com/patent/US11406681B2 ## CPC - A61K 36/9068: Zingiber, e.g. garden ginger - A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals} - A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin - A61K 31/385: having two or more sulfur atoms in the same ring - A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3 - A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof - A61K 36/484: Glycyrrhiza (licorice) - A61K 36/82: Theaceae (Tea family), e.g. camellia - A61K 36/88: Liliopsida (monocotyledons) - A61K 36/8962: Allium, e.g. garden onion, leek, garlic or chives - A61K 36/9066: Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - G01N 33/6893: {related to diseases not provided for elsewhere} - G01N 33/88: involving prostaglandins {or their receptors} - G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)} - G01N 2800/7009: Oxidative stress - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract Managing and treating elevated OS biomarkers in mammals such as companion animals with at least one of the supplements alpha-lipoic acid, carnitine, co-enzyme Q-10, ginger, green tea, licorice, milk thistle, garlic, honey. resveratrol, soybeans, tomatoes, turmeric, vitamin D, vitamin E or selenium. Diagnosing an oxidative stress (OS) in a mammal comprises collecting a sample; screening the sample to detect the presence of an OS biomarker, selectively isoprostane and other antioxidants such as HODE microRNAs. TAC: GSH, MDA, and TNF-alpha. The sample can be saliva. ## Claims ### Claim 1 A method of treating a dog with a diagnosed level above 1.75 ng/ml of the OS isoprostane biomarker comprising: a. formulating a composition to be a combination of at least vitamin D and selenium, alpha-lipoic acid, co-enzyme Q-10, green tea, and turmeric ingredients, b. mixing the ingredients together to be for ingestion by the dog, c. treating the dog with a diagnosed level above 1.75 ng/ml of the OS isoprostane biomarker with the combination composition, and d. reducing the level below 1.75 ng/ml of the OS isoprostane biomarker in the dog so treated by the composition combination. ### Claim 2 (depends on 1) The method for treating oxidative stress (OS) as claimed in claim 1 including treating an elevated HODE OS biomarker in the dog. ### Claim 3 (depends on 1) The method of claim 1 including reducing the OS isoprostane biomarker level by at least 40%. ### Claim 4 (depends on 1) The method of claim 1 including reducing the OS isoprostane biomarker level by at least 40% after five to six months from an elevated level to a level below 1.75 ng/ml, and measuring the OS isoprostane level in saliva from the dog. ### Claim 5 A method of treating a dog with a diagnosed level above 1.75 ng/ml of the OS isoprostane biomarker comprising: a. formulating a composition as a combination of at least Alpha-Lipoic acid in an amount between 50 mg and 100 mg; Co-Enzyme Q-10 in an amount between 5 mg and 20 mg; Green tea in an amount between 50 mg and 200 mg; Selenium in an amount between 5 mcg and 20 mcg; Turmeric (curcumin) in an amount between 20 mg and 300 mg; Vitamin D in an amount between 25 mcg and 150 mcg; and b. treating the dog with a diagnosed level above 1.75 ng/ml of the OS isoprostane biomarker with the combination composition to lower the level below 1.75 ng/ml wherein the OS isoprostane biomarker in the dog so treated by the composition combination is reduced. ### Claim 6 (depends on 5) The method for treating oxidative stress (OS) as claimed in claim 5 including treating an elevated HODE OS biomarker in the dog. ### Claim 7 (depends on 5) The method for treating oxidative stress (OS) as claimed in claim 5 including in the combination cranberries. ### Claim 8 (depends on 5) The method of claim 5 including reducing the isoprostane biomarker level by at least 40%. ### Claim 9 (depends on 5) The method of claim 5 including reducing the isoprostane biomarker level by at least 40% after five to six months from an elevated level to a level below 1.75 ng/ml, and measuring the isoprostane level in saliva from the dog. ### Claim 10 A method of treating a dog with a diagnosed level above 1.75 ng/ml of the OS isoprostane biomarker comprising: a. formulating the composition as a combination at least Alpha-Lipoic acid in an amount of about 20 mg; Co-Enzyme Q-10 in an amount of about 10 mg; Green tea in an amount of about 100 mg; Selenium in an amount of about 10 mcg; Turmeric (curcumin) in an amount of about 100 mg; Vitamin D in an amount of about 75 mcg; and b. treating the dog with a diagnosed level above 1.75 ng/ml of the OS isoprostane biomarker with the combination composition to lower the level below 1.75 ng/ml wherein the OS isoprostane biomarker in the dog so treated by the composition combination is reduced. ### Claim 11 (depends on 10) The method for treating oxidative stress (OS) as claimed in claim 10 including treating an elevated HODE OS biomarker in the dog. ### Claim 12 (depends on 10) The method for treating oxidative stress (OS) as claimed in claim 10 including in the combination blueberries. ### Claim 13 (depends on 10) The method of claim 10 including reducing the isoprostane biomarker level by at least 40%. ### Claim 14 (depends on 10) The method of claim 10 including reducing the isoprostane biomarker level by at least 40% after five to six months from an elevated level to a level below 1.75 ng/ml and measuring the isoprostane level in saliva from the dog. ### Claim 15 A method of treating a dog with a diagnosed level above 1.75 ng/ml of the OS isoprostane biomarker comprising: a. using a composition to reduce the isoprostane marker indicative of oxidative stress (OS) in a dog, b. formulating the composition as a combination consisting of vitamin D and selenium, alpha-lipoic acid, co-enzyme Q-10, green tea, and turmeric ingredients, and c. treating the dog with a level above 1.75 ng/ml of the OS isoprostane biomarker with the combination composition to lower the level below 1.75 ng/ml wherein the OS isoprostane biomarker in the dog so treated by the composition combination is reduced. ### Claim 16 (depends on 15) The method of claim 15 including reducing the isoprostane biomarker level by at least 40%. ### Claim 17 (depends on 15) The method of claim 15 including reducing the isoprostane biomarker level by at least 40% after five to six months from an elevated level to a level below 1.75 ng/ml as measured in saliva from the dog. ### Claim 18 A method of treating a dog with a diagnosed level above 1.75 ng/ml of the OS isoprostane biomarker comprising: a. formulating a composition to consist of a combination of at least Alpha-Lipoic acid in an amount between 50 mg and 100 mg; Co-Enzyme Q-10 in an amount between 5 mg and 20 mg; Green tea in an amount between 50 mg and 200 mg; Selenium in an amount between 5 mcg and 20 mcg; Turmeric (curcumin) in an amount between 20 mg and 300 mg; and Vitamin D in an amount between 25 mcg and 150 mcg; b. mixing the ingredients together for ingestion by the dog, and c. treating the dog with a diagnosed level above 1.75 ng/ml of the OS isoprostane biomarker with the combination composition to lower the level below 1.75 ng/ml wherein the OS isoprostane biomarker in the dog so treated by the composition combination is reduced. ### Claim 19 A method of treating a dog with a diagnosed level above 1.75 ng/ml of the OS isoprostane biomarker a. using a composition to reduce an isoprostane marker indicative of oxidative stress (OS) in a dog, the composition being a combination consisting of Alpha-Lipoic acid in an amount of about 20 mg; Co-Enzyme Q-10 in an amount of about 10 mg; Green tea in an amount of about 100 mg; Selenium in an amount of about 10 mcg; Turmeric (curcumin) in an amount of about 100 mg; and Vitamin D in an amount of about 75 mcg; b. mixing the ingredients together and being for ingestion by the dog, and c. treating the dog with a diagnosed level above 1.75 ng/ml of the OS isoprostane biomarker with the combination composition to lower the level below 1.75 ng/ml wherein the OS isoprostane biomarker in the dog so treated by the composition combination is reduced. ### Claim 20 (depends on 1) The method for treating oxidative stress (OS) as claimed in claim 1 including in the combination blueberries. ### Claim 21 (depends on 1) The method for treating oxidative stress (OS) as claimed in claim 1 including in the combination cranberries. ### Claim 22 (depends on 1) The method for treating oxidative stress (OS) as claimed in claim 1 including in the combination blueberries and cranberries.